PRKAA2 and Alzheimer disease: Finally, given the sex-specific metabolic dysfunction observed in some AD studies (88) and the sex-differences reported in pre-clinical AMPK activator studies (78, 80), one additional potential area of investigation lies in the study of sex-differences in metabolic-targeting as an AD therapeutic intervention.